MX336240B - Furazanobencimidazoles como profarmacos para tratar las enfermedades neoplasicas o autoinmunologicas. - Google Patents

Furazanobencimidazoles como profarmacos para tratar las enfermedades neoplasicas o autoinmunologicas.

Info

Publication number
MX336240B
MX336240B MX2012000611A MX2012000611A MX336240B MX 336240 B MX336240 B MX 336240B MX 2012000611 A MX2012000611 A MX 2012000611A MX 2012000611 A MX2012000611 A MX 2012000611A MX 336240 B MX336240 B MX 336240B
Authority
MX
Mexico
Prior art keywords
amino
lower alkyl
alkoxy
alkyl
lower alkoxy
Prior art date
Application number
MX2012000611A
Other languages
English (en)
Other versions
MX2012000611A (es
Inventor
Jens Pohlmann
Felix Bachmann
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of MX2012000611A publication Critical patent/MX2012000611A/es
Publication of MX336240B publication Critical patent/MX336240B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (II) en donde (a) representa un residuo de benceno divalente que está substituido o no substituido por uno o dos substituyentes adicionales seleccionados independientemente de alquilo inferior, halo-alquilo inferior, hidroxi-alquilo inferior, alcoxi inferior-alquilo inferior, aciloxi-alquilo inferior, fenilo, hidroxi, alcoxi inferior, hidroxi-alcoxi inferior, alcoxi inferior-alcoxi inferior, fenil-alcoxi inferior, alquilcarboniloxi inferior, amino, mono(alquilo inferior)amino, di(alquilo inferior) amino, mono(alquenilo inferior) amino, di (alquenilo inferior) amino, alcoxicarbonilamino inferior, alquilcarbonilamino inferior, amino substituido en donde los dos substituyentes sobre el nitrógeno forman junto con el nitrógeno, el heterociclilo, alquilcarbonilo inferior, carboxi, alcoxicarbonilo inferior, ciano, halógeno, y nitro; o en donde dos substituyentes adyacentes pueden ser metilendioxi; o un residuo de piridina divalente (Z = N) que está substituido o no substituido adicionalmente por alquilo inferior, alcoxi inferior, alcoxi inferior-alcoxi inferior, amino, opcionalmente substituido por uno o dos substituyentes seleccionados de alquilo inferior, alquenilo inferior y alquilcarbonilo, halo-alquilo inferior, alcoxi inferior-alquilo inferior, o halógeno; R1 representa hidrógeno, alquilcarbonilo inferior, hidroxi-alquilo inferior o ciano-alquilo inferior; y R2 representa un grupo seleccionado de: (b), (c) y (d); o las sales de los mismos farmacéuticamente aceptables.
MX2012000611A 2009-07-27 2010-07-26 Furazanobencimidazoles como profarmacos para tratar las enfermedades neoplasicas o autoinmunologicas. MX336240B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09166469 2009-07-27
PCT/EP2010/060803 WO2011012577A1 (en) 2009-07-27 2010-07-26 Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases

Publications (2)

Publication Number Publication Date
MX2012000611A MX2012000611A (es) 2012-01-27
MX336240B true MX336240B (es) 2016-01-13

Family

ID=41226617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000611A MX336240B (es) 2009-07-27 2010-07-26 Furazanobencimidazoles como profarmacos para tratar las enfermedades neoplasicas o autoinmunologicas.

Country Status (25)

Country Link
US (1) US8802858B2 (es)
EP (1) EP2459553B1 (es)
JP (1) JP5576485B2 (es)
KR (1) KR101758400B1 (es)
CN (1) CN102471329B (es)
AU (1) AU2010277688B2 (es)
BR (1) BR112012001817B8 (es)
CA (1) CA2767875C (es)
CY (1) CY1115809T1 (es)
DK (1) DK2459553T3 (es)
EA (1) EA021380B1 (es)
ES (1) ES2524119T3 (es)
HK (1) HK1166316A1 (es)
HR (1) HRP20141120T1 (es)
IL (1) IL217195A (es)
MX (1) MX336240B (es)
NZ (1) NZ597376A (es)
PL (1) PL2459553T3 (es)
PT (1) PT2459553E (es)
RS (1) RS53679B1 (es)
SI (1) SI2459553T1 (es)
TW (1) TWI457337B (es)
UA (1) UA106763C2 (es)
WO (1) WO2011012577A1 (es)
ZA (1) ZA201200228B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2666015T3 (pl) * 2011-01-21 2017-06-30 Basilea Pharmaceutica Ag Zastosowanie statminy jako biomarkera odpowiedzi lekowej na furazanobenzoimidazole
HUE031162T2 (en) 2011-01-21 2017-07-28 Basilea Pharmaceutica Ag Use of Glu tubulin as a biomarker for drug response to furazanobenzimidazoles
WO2012098207A1 (en) 2011-01-21 2012-07-26 Basilea Pharmaceutica Ag Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
HUE032187T2 (en) * 2011-02-24 2017-09-28 Basilea Pharmaceutica Ag Use of acetylated tubulin as a biomarker for response to furazanobenzimidazoles
PL2691533T3 (pl) 2011-03-29 2017-09-29 Basilea Pharmaceutica Ag Zastosowanie fosfo-Akt jako biomarkera odpowiedzi na leki
US9558575B2 (en) 2012-02-28 2017-01-31 Blackberry Limited Methods and devices for selecting objects in images
ITRM20130248A1 (it) * 2013-04-24 2014-10-25 Medivis S R L Formulazioni di riboflavina per il cross-linking transepiteliale.
WO2015173341A1 (en) * 2014-05-13 2015-11-19 Basilea Pharmaceutica Ag Dosage principle for anti-cancer furazanylbenzimidazoles
CN108139405B (zh) * 2015-10-22 2022-06-10 巴斯利尔药物国际股份公司 Eb1作为药物应答的生物标记物的用途
TW201838965A (zh) * 2017-04-20 2018-11-01 印度商Ｐｉ工業公司 新穎的苯胺化合物
CA3058695A1 (en) 2017-04-26 2018-11-01 Basilea Pharmaceutica International AG Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
EP3624790A1 (en) 2017-05-16 2020-03-25 Basilea Pharmaceutica International AG Novel dosage principle for drugs useful for treating neoplastic diseases
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US20220031670A1 (en) 2018-09-20 2022-02-03 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
CN111454254B (zh) 2020-04-26 2023-06-02 云白药征武科技(上海)有限公司 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用
CN111423429A (zh) * 2020-05-19 2020-07-17 江西科技师范大学 苯并咪唑联呋咱类系列化合物及其合成方法
WO2022053549A1 (en) 2020-09-10 2022-03-17 Basilea Pharmaceutica International AG Use of c-myc as a biomarker of drug response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
US20040034037A1 (en) * 2002-02-06 2004-02-19 Harbeson Scott L. Heteroaryl compounds useful as inhibitors of GSK-3
PL1636215T3 (pl) * 2003-05-23 2008-09-30 Basilea Pharmaceutica Ag Furazanobenzymidazole
EP1723138B1 (en) * 2004-02-11 2010-07-14 Basilea Pharmaceutica AG Substituted benzimidazoles and their use for inducing apoptosis

Also Published As

Publication number Publication date
JP5576485B2 (ja) 2014-08-20
NZ597376A (en) 2014-01-31
CA2767875A1 (en) 2011-02-03
JP2013500304A (ja) 2013-01-07
IL217195A (en) 2014-03-31
TWI457337B (zh) 2014-10-21
MX2012000611A (es) 2012-01-27
CN102471329A (zh) 2012-05-23
US8802858B2 (en) 2014-08-12
CY1115809T1 (el) 2017-01-25
EP2459553B1 (en) 2014-10-01
DK2459553T3 (da) 2014-11-03
BR112012001817B8 (pt) 2021-05-25
CA2767875C (en) 2016-03-15
US20120264792A1 (en) 2012-10-18
HK1166316A1 (en) 2012-10-26
ZA201200228B (en) 2012-09-26
UA106763C2 (uk) 2014-10-10
CN102471329B (zh) 2014-11-05
PT2459553E (pt) 2014-11-24
RS53679B1 (en) 2015-04-30
IL217195A0 (en) 2012-02-29
KR20120055571A (ko) 2012-05-31
PL2459553T3 (pl) 2015-03-31
BR112012001817A2 (pt) 2016-03-15
TW201107318A (en) 2011-03-01
SI2459553T1 (sl) 2015-01-30
AU2010277688B2 (en) 2013-12-05
KR101758400B1 (ko) 2017-07-14
WO2011012577A1 (en) 2011-02-03
EA201200189A1 (ru) 2012-08-30
EP2459553A1 (en) 2012-06-06
AU2010277688A1 (en) 2012-02-09
EA021380B1 (ru) 2015-06-30
HRP20141120T1 (hr) 2015-01-30
ES2524119T3 (es) 2014-12-04
BR112012001817B1 (pt) 2020-09-29

Similar Documents

Publication Publication Date Title
NZ597376A (en) Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases
TW200612958A (en) Substituted imidazole derivatives
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
MA35451B1 (fr) Dérivés de pyrrolopyrimidine et de purine
NZ591166A (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
MX2007004699A (es) Derivados de indol y bencimidazol.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MY169179A (en) Novel piperidine compound or salt thereof
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
MX2009005071A (es) Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
EA201170595A1 (ru) ПРОИЗВОДНОЕ ФЕНАНТРОИНДОЛИЗИДИНА И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА
NZ595705A (en) Protease inhibitors
MX341342B (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
EA201170596A1 (ru) ФЕНАНТРОИНДОЛИЗИДИНОВОЕ СОЕДИНЕНИЕ И ИНГИБИТОР NFkB, СОДЕРЖАЩИЙ ЕГО В КАЧЕСТВЕ ДЕЙСТВУЮЩЕГО ИНГРЕДИЕНТА
MX369470B (es) Medios y método para el tratamiento de tumores sólidos.
EA201101298A1 (ru) Аддитивные соли трометамина с производными азабифениламинобензойной кислоты в качестве ингибиторов dhodh
WO2013060744A3 (en) 1, 2, 4 - oxadiazole derivatives as ethr inhibitors for use in the treatment tuberculosis
MX348601B (es) Composiciones para el cuidado oral y de la piel con base en un 3,3´-dialquil-1,1´-bifenil-2,2´-diol o un 3,3´-dialquenil-1,1´-bif enil-2,2´-diol.